Gentag, Inc. and The CORE Institute® are pleased to announce the signing of a license agreement to develop and commercialize a disposable wireless skin patch to allow patients to self monitor themselves in the comfort of their homes after orthopedic surgery in hospitals through the use of cell phones.
The technology will help reduce post-orthopedic surgical-related medical costs by reducing the time spent in hospitals and detecting possible problems much earlier with less pain and risk, and costing much less than existing technology.
The technology combines advanced MEMS sensors and Gentag's disposable wireless platform sensor that is directly compatible with cell phones integrating standard NFC-ISO 15693 hybrid reader chip technology. Such cell phones include the iPhone via a soon-to-be released RFID retrofit, thereby ensuring broad access by consumers to the technology. Clinical trials are expected to begin in 2010.
"The CORE Institute®, their physicians and research team have the required medical expertise and involvement in the orthopedics arena to bring this new technology through the FDA approval process to benefit patients worldwide," announced Dr. John Peeters, the founder of Gentag. "We are pleased to sign this agreement and look forward to supporting The CORE Institute® and its partners to commercialize this new technology and other related technologies."
"The CORE Institute® is pleased to secure the funding required for the final development of this important technology platform that will decrease the cost of care, while improving patient safety and outcomes, by giving patients the tools to detect post orthopedic surgery complications in the comfort of their homes," announced David Jacofsky, MD, the Chairman and CEO of The CORE Institute®.
Early bilateral oophorectomy linked to increased Alzheimer's disease risk